Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
NCT04217629
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class
Conditions
Sepsis
Interventions
DRUG:
SY-005
Sponsor
Suzhou Yabao Pharmaceutical R&D Co., Ltd.